title: Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions.
abstract: Venous thrombosis is a common complication in cancer patients, and some cancer chemotherapies are associated with an increased risk of venous thromboembolism. The regulatory mechanisms that control thrombus formation and subsequent resolution in patients with cancer, however, are incompletely understood, and novel treatments for cancer-associated thrombosis may arise from a better understanding of such mechanisms. In this chapter, pathways that regulate cancer-associated thrombus formation are outlined, and the effects of anti-angiogenic cancer chemotherapies on venous thrombus resolution are highlighted. Potentially pro-thrombotic effects of anti-angiogenic agents are important considerations when managing the complications of venous thrombosis in cancer patients.
authors.affiliation: Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
authors.forename: Alice
authors.initials: A
authors.lastname: Prodger
authors.affiliation: Academic Department of Vascular Surgery, King's College London, London, UK.
authors.forename: Prakash
authors.initials: P
authors.lastname: Saha
authors.affiliation: Academic Department of Vascular Surgery, King's College London, London, UK.
authors.forename: Alberto
authors.initials: A
authors.lastname: Smith
authors.affiliation: Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK. Cee31@cam.ac.uk.
authors.forename: Colin E
authors.initials: CE
authors.lastname: Evans
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019468:Disease Management; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D016017:Odds Ratio; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012306:Risk; D013925:Thromboplastin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D054556:Venous Thromboembolism / Q000139:chemically induced* / Q000473:pathology; D020246:Venous Thrombosis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D013925:Thromboplastin
keywords: Anti-angiogenic; Cancer; Chemotherapy; Hypoxia; Resolution; Thrombosis